Novartis execs on compliance: “Why be afraid of the truth?”
Novartis’s Shannon Thyme Klinger and Klaus Moosmayer talk to GIR about how the pharmaceutical company changed its approach to compliance in the midst of a series of government investigations.
To read more
Subscribe to Global Investigations Review
Subscribe and start reading now
Global Investigations Review (GIR) is the hub for global coverage of corporate investigations and their aftermath. Keep up to date with significant developments in the corporate investigations world.